CYPRESS Phase 3 Misses Primary Endpoint, but FDA Signals Path Forward for Ampreloxetine
TBPH sits 30% above its 52-week low of $13.08.
Summary
Theravance's CYPRESS Phase 3 study of ampreloxetine missed its primary endpoint, but post hoc analyses showed significant effects in a focused patient group, and the FDA has agreed to discuss a new pivotal trial design.
Key Events · Product Development and Regulatory · TBPH
-
CYPRESS Primary Endpoint Missed
The Phase 3 CYPRESS Study (0197) of ampreloxetine in nOH associated with MSA failed to show statistical significance on the primary endpoint — change in OHSA composite score at week 8 during randomized withdrawal.
-
Post Hoc Analyses Show Benefit
In a confirmed symptomatic nOH population (n=47), average OHSA, OHDAS, and OHQ scores over weeks 2–8 showed statistically significant improvements (LS mean differences of -1.06, -1.27, and -1.24; all p≤0.001).
-
FDA Regulatory Path
A May 2026 Type B meeting concluded existing data would not support approval, but an additional pivotal trial could offer a path forward. FDA granted a Type C meeting request to align on future study design.
-
CVR Implications
Ampreloxetine is the subject of the contingent value right in the pending Zymeworks acquisition; its regulatory outcome directly affects whether CVR holders receive any payout.
Analysis · TBPH · Life Sciences
Ampreloxetine's Phase 3 CYPRESS study failed its primary endpoint, yet post hoc analyses in a narrower patient population showed statistically significant benefits, and the FDA has indicated an additional pivotal trial could support approval. This matters because ampreloxetine is the lead asset tied to the contingent value right (CVR) in the pending Zymeworks acquisition — its regulatory fate directly affects whether shareholders receive the CVR payout. The mixed data keeps the program alive but adds uncertainty and likely delays any potential approval.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 29.6% of the 2856 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TBPH was trading at $17.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $884.2M. The 52-week trading range was $13.08 to $21.03. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.